GO
Loading...

Endo Health Solutions Inc

More

  • NEW YORK, Sept 17- Auxilium Pharmaceuticals shares surged in brisk premarket trading Wednesday, a day after receiving an unsolicited offer from Endo International. Analysts said the offer could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc, whose U.S. shares were down 11.3 percent in light trading.

  • Sept 17- Auxilium Pharmaceuticals Inc said it would not withdraw its offer to buy Canadian eye drug maker QLT Inc and adopted a poison pill, a day after receiving an unsolicited buyout offer from Endo International Plc.

  • Sept 17- Auxilium Pharmaceuticals Inc adopted a poison pill with a 15 percent trigger, a day after an unsolicited $2.2 billion buyout offer from Endo International Plc.

  • Sept 16- Endo International Plc made an unsolicited offer to buy Auxilium Pharmaceuticals Inc for about $2.2 billion, which analysts said could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc.

  • Sept 16- Specialty healthcare company Endo International Plc offered to buy Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock to expand its men's healthcare products business.

  • Endo offers to buy Auxilium Pharma for about $2.2 bln Tuesday, 16 Sep 2014 | 5:01 PM ET

    Sept 16- Endo International Plc offered to acquire Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock. The offer of $28.10 per share represents a premium of 30.6 percent to Auxilium's Tuesday closing price of $21.52 on the Nasdaq. Endo said it intends to fund the transaction through cash on hand and debt financing.

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in the first of two identical studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in two studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • After-Hours Buzz: CSTR, PRGS & More Thursday, 3 Jan 2013 | 4:39 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • After-Hours Buzz: Juniper, Boston Beer & More Wednesday, 12 Dec 2012 | 5:42 PM ET

    Check out which companies are making headlines after the bell Wednesday.

  • Shares of Samsung Electronics, which have surged almost 35 percent since the start of the year, closed at an all-time high on Thursday boosted by expectations that its smartphone business will continue to drive strong profit growth.

  • Here Are Small Cap Values: Gabelli Wednesday, 21 Nov 2012 | 1:39 PM ET

    With bigger companies looking to grow, many may look to acquire smaller firms. That’s one of the reasons Mario Gabelli, chairman of Gamco Investors, sees opportunity in small-cap equities.

  • Oct 11- Endo Health Solutions Inc:. *FDA- became aware of cases of a serious blood disorder in individuals abusing. *FDA says the disorder related to Endo's Opana ER resulted in kidney failure.

  • Opana, a powerful opioid painkiller containing oxymorphone, is produced by Endo Pharmaceuticals. The blood disorder, thrombotic thrombocytopenic purpura, resulted in kidney failure requiring dialysis in some cases and at least one death, the Food and Drug Administration said.

  • Abuse of painkiller Opana can cause blood disorder-US FDA Thursday, 11 Oct 2012 | 12:12 AM ET

    Opana is produced by Endo Pharmaceuticals. The blood disorder, thrombotic thrombocytopenic purpura, resulted in kidney failure requiring dialysis in some cases, and at least one death, the Food and Drug Administration said. The FDA said problems appear to occur with Opana ER only when it is abused and injected intravenously.

  • Oct 9- Endo Health Solutions Inc:. Reuters Station users, click. 1568. Reuters Station users, click. 4899.

  • Oct 5- Endo Health Solutions Inc:. *Oppenheimer cuts Endo Health Solutions Inc price target to $42 from. Reuters Station users, click. 1568.

  • Oct 5- Endo Health Solutions Inc:. *UBS cuts Endo Pharmaceuticals price target to $45 from $50; rating. Reuters Station users, click. 1568.

  • Oct 5- Endo Health Solutions Inc:. *ThinkEquity cuts Endo Health Solutions price target to $40 from $45;. Reuters Station users, click. 1568.

  • Oct 5- Endo Health Solutions Inc:. *RBC cuts Endo Health Solutions Inc to sector perform from outperform. Reuters Station users, click. 1568.